{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:18:09Z","timestamp":1785442689145,"version":"3.56.0"},"reference-count":56,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Cardiac amyloidosis (CA), a significant condition resulting in infiltrative cardiomyopathy and heart failure with preserved ejection fraction (HFpEF), is caused by extracellular deposition of amyloid fibrils in the heart. Even though this has been known for an extended period, its prevalence in elderly patients with heart failure is increasingly being recognized. Recent advances in diagnosis with non-invasive methods like technetium pyrophosphate-labeled cardiac scintigraphy (i.e., Tc-PYP scan) and treatment options with tafamidis have played a pivotal role in awareness of the burden of this disease. Management of cardiac complications like heart failure, atrial arrhythmias, conduction block, ventricular arrhythmias, coronary artery disease, and aortic stenosis is now more critical than ever. We aim to review and outline the recent advances in diagnoses of CA. We also review management strategies for cardiac complications of CA with a brief summary of disease-modifying therapies.<\/ns4:p>","DOI":"10.12688\/f1000research.130285.1","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T06:40:19Z","timestamp":1676875219000},"page":"192","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies"],"prefix":"10.12688","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3016-0078","authenticated-orcid":false,"given":"Maharshi","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid","family":"Siddiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Labdhi","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaahnavee","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanishka","family":"Uttam Chandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhriti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2851-2862","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis.","volume":"75","author":"M Hanna","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11864-020-00738-8","article-title":"Advances in the Treatment of Cardiac Amyloidosis.","volume":"21","author":"A Macedo","year":"2020","journal-title":"Curr. Treat. Options in Oncol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"s30-s35","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis.","volume":"18","author":"A Martinez-Naharro","year":"2018","journal-title":"Clin. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination.","volume":"8","author":"A Porcari","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"712-724","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.","volume":"8","author":"V Hahn","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms23010025","article-title":"Molecular Mechanisms of Cardiac Amyloidosis.","volume":"23","author":"Y Saito","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"289-311","DOI":"10.1007\/s40119-021-00222-w","article-title":"Multidisciplinary Approaches for Transthyretin Amyloidosis.","volume":"10","author":"H Koike","year":"2021","journal-title":"Cardiol. Ther."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2342-2351","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.","volume":"24","author":"A Aimo","year":"May 2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"661-673","DOI":"10.2147\/VHRM.S295376","article-title":"Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms.","volume":"17","author":"G Korosoglou","year":"2021","journal-title":"Vasc. Health Risk Manag."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/biomedicines10040903","article-title":"Advanced Imaging in Cardiac Amyloidosis.","volume":"10","author":"D Waldmeier","year":"2022","journal-title":"Biomedicines."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fcvm.2021.751293","article-title":"Cardiac Amyloidosis: A Review of Current Imaging Techniques.","volume":"8","author":"Y Razvi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"426-430","DOI":"10.1016\/j.jjcc.2015.11.004","article-title":"Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis.","volume":"68","author":"L Zhao","year":"2016","journal-title":"J. Cardiol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1554-1568","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.","volume":"42","author":"P Garcia-Pavia","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1128-1139","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.","volume":"6","author":"H Yamamoto","year":"2019","journal-title":"ESC Heart Fail."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"342-344","DOI":"10.1093\/eurheartj\/ehab609","article-title":"Longitudinal strain in the management of cardiac AL amyloidosis: do we need it?","volume":"43","author":"C Rapezzi","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/diagnostics12030627","article-title":"Multimodal Imaging and Biomarkers in Cardiac Amyloidosis.","volume":"12","author":"M Jung","year":"2022","journal-title":"Diagnostics."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1304-1311","DOI":"10.1093\/ehjci\/jeab095","article-title":"99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.","volume":"22","author":"C Quarta","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Imaging."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"604-609","DOI":"10.1007\/s12350-020-02516-3","article-title":"A cardiology fellow\u2019s take-home points from ASNC\u2019s Webinar: Cases in Tc 99m-PYP evaluation of ATTR cardiac amyloidosis - interpretation and reporting.","volume":"28","author":"M Shetty","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e25582","DOI":"10.1097\/MD.0000000000025582","article-title":"False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain.","volume":"100","author":"Y Zeng","year":"2021","journal-title":"Medicine."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1652-1662","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography.","volume":"41","author":"S Dorbala","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"50-59","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"11C-Pittsburgh B PET Imaging in Cardiac Amyloidosis.","volume":"8","author":"S Lee","year":"2015","journal-title":"JACC Cardiovasc. Imaging."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12872-021-02292-z","article-title":"Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.","volume":"21","author":"Z Wu","year":"2021","journal-title":"BMC Cardiovasc. Disord."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"488-505","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR Amyloidosis: Current and Emerging Management Strategies.","volume":"3","author":"J Griffin","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3369-3374","DOI":"10.1002\/ehf2.13411","article-title":"Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey.","volume":"8","author":"G Tini","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"177-188","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.","volume":"3","author":"K Jujo","year":"2016","journal-title":"ESC Heart Fail."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1451-1461","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction.","volume":"385","author":"S Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1089-1098","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.","volume":"387","author":"S Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3556-3564","DOI":"10.1002\/ehf2.14082","article-title":"Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants.","volume":"9","author":"O Touboul","year":"July 2022","journal-title":"ESC Heart Fail."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"913-921","DOI":"10.1111\/pace.13992","article-title":"Catheter ablation of atrial fibrillation in cardiac amyloidosis.","volume":"43","author":"E Black-Maier","year":"2020","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1740-1748","DOI":"10.1002\/ehf2.13851","article-title":"Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.","volume":"9","author":"M Papathanasiou","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"56-67","DOI":"10.1093\/eurheartj\/ehab441","article-title":"Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.","volume":"43","author":"R Wang","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"790-796","DOI":"10.1007\/s12350-019-01644-9","article-title":"Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management.","volume":"26","author":"V Singh","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fcvm.2022.1061717","article-title":"Clinical challenges in the management of cardiac amyloidosis complicating aortic stenosis and coronary artery disease.","volume":"9","author":"M Raval","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"577-579","DOI":"10.1016\/j.jaccao.2021.09.004","article-title":"Aging, Aortic Stenosis, and Transthyretin Cardiac Amyloidosis.","volume":"3","author":"S Bokhari","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"67-76","DOI":"10.1016\/j.hjc.2021.11.001","article-title":"Prevalence and outcomes of concomitant cardiac amyloidosis and aortic stenosis: A systematic review and meta-analysis.","volume":"64","author":"J Ho","year":"2022","journal-title":"Hell. J. Cardiol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3188-3197","DOI":"10.1002\/ehf2.13876","article-title":"Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta-analysis.","volume":"9","author":"F Cannata","year":"June 2022","journal-title":"ESC Heart Fail."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"207-211","DOI":"10.1007\/s10840-019-00517-y","article-title":"Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?","volume":"55","author":"J Milner","year":"2019","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1227-1236","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.","volume":"24","author":"A Porcari","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"740-750","DOI":"10.1002\/ehf2.13663","article-title":"Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis.","volume":"9","author":"K Fischer","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1601-1687","DOI":"10.1093\/europace\/euv319","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.","volume":"17","year":"August 2015","journal-title":"Europace."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"793-798","DOI":"10.1111\/jce.12123","article-title":"Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis.","volume":"24","author":"G Lin","year":"2013","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"11631","DOI":"10.3390\/ijerph182111631","article-title":"Right Ventricular Endocardial Mapping and a Potential Arrhythmogenic Substrate in Cardiac Amyloidosis\u2014Role of ICD.","volume":"18","author":"A Li\u017cewska-Springer","year":"2021","journal-title":"Int. J. Environ. Res. Public Health."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"516-521","DOI":"10.1016\/j.jaccao.2021.05.007","article-title":"Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis.","volume":"3","author":"R Witteles","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e13663","DOI":"10.1111\/ctr.13663","article-title":"Mechanical circulatory support for cardiac amyloidosis.","volume":"33","author":"M Kittleson","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"467-487","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies.","volume":"3","author":"G Bianchi","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3252-3260","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.","volume":"38","author":"E Kastritis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"266-278","DOI":"10.5045\/br.2021.2021121","article-title":"Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis.","volume":"56","author":"J Hur","year":"2021","journal-title":"Blood Res."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"73-77","DOI":"10.14797\/mdcvj.1071","article-title":"Future Directions in Cardiac Amyloidosis.","volume":"18","author":"B Trachtenberg","year":"2022","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.","volume":"15","author":"P Elliott","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"445-450","DOI":"10.1007\/s40256-022-00526-9","article-title":"Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.","volume":"22","author":"M Rozenbaum","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"529-538","DOI":"10.1093\/ehjqcco\/qcab031","article-title":"Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.","volume":"8","author":"M Rozenbaum","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"59-72","DOI":"10.14797\/mdcvj.1050","article-title":"Cardiac Amyloidosis Treatment.","volume":"18","author":"L Stern","year":"2022","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1646-1657","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.","volume":"22","author":"H Schmidt","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"865-886","DOI":"10.1007\/s40120-021-00268-x","article-title":"Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.","volume":"10","author":"A Yarlas","year":"2021","journal-title":"Neurol. Ther."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"558-559","DOI":"10.1056\/NEJMe2110557","article-title":"Gene Editing \u2014 A Cure for Transthyretin Amyloidosis?","volume":"385","author":"M Maurer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref56","article-title":"Cardiac amyloidosis.","year":"2022"}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/12-192\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/12-192\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/12-192\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T06:05:13Z","timestamp":1678255513000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/12-192\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":56,"URL":"https:\/\/doi.org\/10.12688\/f1000research.130285.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.143029.r164947","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.143029.r164944","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.143029.r164947","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.143029.r164944","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/12-192\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.143029.r164947, Apoorva Kondapally, Willis-Knighton Medical Center, Shreveport, LA, 06 Mar 2023, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/12-192\/v1#referee-response-164947","order":0,"name":"referee-response-164947","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.143029.r164944, Bhavi Trivedi, Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, 08 Mar 2023, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/12-192\/v1#referee-response-164944","order":1,"name":"referee-response-164944","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}